Cascadian Therapeutics Inc logo

CASC - Cascadian Therapeutics Inc Share Price

$10.02 0.0  0.0%

Last Trade - 08/03/18

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6396
Bullish
Bearish
Unlock CASC Revenue
Momentum
Relative Strength (%)
1m +1.05%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 6.25 2.67
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2017, Cascadian Therapeutics Inc (USA) revenues was not reported. Net loss applicable to common stockholders excluding extraordinary items increased 79% to $108M. Higher net loss reflects Research and development increase of 60% to $44M (expense), Other Income decrease from $50K (income) to $0K, Foreign Exchange Gain/Loss decrease from $1K (income) to $5K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CASC Revenue Unlock CASC Revenue

Net Income

CASC Net Income Unlock CASC Revenue

Normalised EPS

CASC Normalised EPS Unlock CASC Revenue

PE Ratio Range

CASC PE Ratio Range Unlock CASC Revenue

Dividend Yield Range

CASC Dividend Yield Range Unlock CASC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CASC EPS Forecasts Unlock CASC Revenue
Profile Summary

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Directors
Last Annual December 31st, 2017
Last Interim December 31st, 2017
Incorporated September 7, 2007
No. of Shareholders: 16,707
No. of Employees: 71
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 55,317,212
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CASC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CASC
Upcoming Events for CASC
Frequently Asked Questions for Cascadian Therapeutics Inc
What is the Cascadian Therapeutics Inc share price?

As of 08/03/18, shares in Cascadian Therapeutics Inc are trading at $10.02, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Cascadian Therapeutics Inc share price performed this year?

Shares in Cascadian Therapeutics Inc are currently trading at $10.02 and the price has moved by 0.136k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cascadian Therapeutics Inc price has moved by 0.111k% over the past year.

What are the analyst and broker recommendations for Cascadian Therapeutics Inc?

Of the analysts with advisory recommendations for Cascadian Therapeutics Inc, there are there are currently 1 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cascadian Therapeutics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Cascadian Therapeutics Inc next release its financial results?

Cascadian Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2018-12-31
What is the Cascadian Therapeutics Inc dividend yield?

Cascadian Therapeutics Inc does not currently pay a dividend.

Does Cascadian Therapeutics Inc pay a dividend?

Cascadian Therapeutics Inc does not currently pay a dividend.

When does Cascadian Therapeutics Inc next pay dividends?

Cascadian Therapeutics Inc does not currently pay a dividend.

How do I buy Cascadian Therapeutics Inc shares?

To buy shares in Cascadian Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cascadian Therapeutics Inc?

Shares in Cascadian Therapeutics Inc are currently trading at $10.02, giving the company a market capitalisation of £n/a.

Where are Cascadian Therapeutics Inc shares listed? Where are Cascadian Therapeutics Inc shares listed?

Here are the trading details for Cascadian Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: CASC
What kind of share is Cascadian Therapeutics Inc?

We were not able to load our ranking data for Cascadian Therapeutics Inc

Is there a Cascadian Therapeutics Inc share price forecast 2020?

We were not able to load any forecast data for Cascadian Therapeutics Inc.

How can I tell whether the Cascadian Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cascadian Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 86.02%. At the current price of $10.02, shares in Cascadian Therapeutics Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cascadian Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Cascadian Therapeutics Inc.

Who are the key directors of Cascadian Therapeutics Inc?

We were unable to find the directors for Cascadian Therapeutics Inc.

Who are the major shareholders of Cascadian Therapeutics Inc?

Here are the top five shareholders of Cascadian Therapeutics Inc based on the size of their shareholding:

Similar to CASC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.